The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys

By Durbin A.P.   Wyatt L.S.   Siew J.   Moss B.   Murphy B.R.  

Vaccine, Vol. 16, Iss. 13, 1998-08 ,pp. : 1324-1330

Elsevier

Access to resources Recommend Favorite

Protective efficacy of vaccination by recombinant vaccinia virus against Neospora caninum infection

By Nishikawa Y.   Inoue N.   Xuan X.   Nagasawa H.   Igarashi I.   Fujisaki K.   Otsuka H.   Mikami T.  

Vaccine, Vol. 19, Iss. 11, 2001-12 ,pp. : 1381-1390

Elsevier

Access to resources Recommend Favorite

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

By Arribillaga L.   de Cerio A.L.D.   Sarobe P.   Casares N.   Gorraiz M.   Vales A.   Bruna-Romero O.   Borras-Cuesta F.   Paranhos-Baccala G.   Prieto J.   Ruiz J.   Lasarte J.J.  

Vaccine, Vol. 21, Iss. 3, 2002-12 ,pp. : 202-210

Elsevier

Access to resources Recommend Favorite

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) - A meeting report of the WHO Programme for Vaccine Development

By Crowe J.E.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 415-421

Elsevier

Access to resources Recommend Favorite

Protective effects against simian immunodeficiency virus agm (SIVagm) infection in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the SIVagm envelope gene

By Ibuki K.   Ido E.   Funahashi S.-i.   Miura T.   Hayami M.   Shida H.  

Vaccine, Vol. 18, Iss. 5, 1999-10 ,pp. : 511-516

Elsevier

Access to resources Recommend Favorite